恒瑞医药(01276)获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries have been granted clinical trial approval for HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Adalimumab injection, Bevacizumab injection, SHR-A2102 for injection, Famitinib malate capsules, and Darsylis sulfate tablets [1] - The approved clinical trials are set to commence in the near future, reflecting the company's ongoing commitment to expanding its product offerings [1]